Fertomid 100 mg (Clomiphene)

Product Overview

Fertomid 100 mg is a prescription oral medication manufactured by Cipla Limited, a globally recognized pharmaceutical company based in India. The product is formulated as a tablet containing 100 mg of Clomiphene citrate, a well‑documented selective estrogen receptor modulator. Each strip contains ten tablets, and the available pack sizes are 30, 60, or 90 tablets, allowing patients to purchase an appropriate supply for a full treatment course. The medication is intended for women diagnosed with ovulatory dysfunction, a common cause of female infertility. Clinical guidelines recommend its use when other first‑line interventions have not resulted in satisfactory ovulation. The packaging follows a standard blister strip design that protects each tablet from moisture and contamination. The strip is sealed to maintain potency throughout the shelf life, which is typically three years from the manufacturing date when stored at room temperature. Patients receiving Fertomid are usually monitored through ultrasound or hormonal assays to assess follicular development and to adjust dosing as needed. This monitoring helps reduce the risk of ovarian hyperstimulation and ensures the safest possible treatment pathway.

What is Fertomid 100 mg?

Fertomid 100 mg belongs to the class of non‑steroidal fertility agents known as selective estrogen receptor modulators (SERMs). The active compound, Clomiphene citrate, functions by interacting with estrogen receptors in the hypothalamus, thereby altering the negative feedback loop that regulates gonadotropin release. This mechanism stimulates the pituitary gland to secrete increased amounts of follicle‑stimulating hormone (FSH) and luteinizing hormone (LH), hormones that are essential for the maturation of ovarian follicles. Fertomid is indicated specifically for women who experience irregular or absent ovulation, a condition that can be associated with polycystic ovary syndrome (PCOS), hypothalamic amenorrhea, or other endocrine disturbances. The drug is not a hormone itself; rather, it mimics the effects of estrogen in certain brain regions while blocking it in others. This selective activity enables Fertomid to “trick” the brain into producing more reproductive hormones without delivering estrogenic activity to peripheral tissues. The medication has been studied extensively in peer‑reviewed literature and is listed on authoritative medical databases such as PubMed and the National Institutes of Health’s clinical trial registry.

Uses and Benefits

Clinicians prescribe Fertomid primarily to induce ovulation in women who have difficulty conceiving due to anovulation or oligo‑ovulation. The therapeutic goal is to increase the probability of natural conception without the need for invasive procedures such as in‑vitro fertilization. In practice, Fertomid can be used alone or as part of a broader fertility protocol that may include timed intercourse, intrauterine insemination (IUI), or controlled ovarian stimulation. The benefits of using Fertomid include its oral administration, low cost relative to injectable gonadotropins, and a well‑characterized safety profile when used according to recommended protocols. Studies have shown that approximately 70 % of women with polycystic ovary syndrome who take Clomiphene experience ovulation within three treatment cycles, and around 30‑40 % achieve pregnancy within six cycles. Additionally, the medication is widely available and can be obtained through licensed online pharmacies that adhere to strict quality standards. Beyond its primary indication, Fertomid may be employed off‑label in certain research settings to evaluate its efficacy in male factor infertility or in assisted reproduction techniques. However, any off‑label use should be supervised by a qualified healthcare professional who can assess risks and benefits.

How It Works

The pharmacodynamics of Clomiphene citrate involve selective binding to estrogen receptors in the hypothalamic neurons. By antagonizing estrogen’s inhibitory signal, Clomiphene prompts the hypothalamus to increase the release of gonadotropin‑releasing hormone (GnRH). This cascade leads to heightened secretion of FSH and LH from the anterior pituitary gland. Elevated FSH promotes the recruitment and development of multiple ovarian follicles, while the LH surge triggers the final maturation step that may culminate in ovulation. Because Clomiphene has partial agonist activity in some tissues, it can produce a milder estrogenic effect in the endometrium, which may improve endometrial receptivity in some patients. Nevertheless, the response is highly individualized; dosage adjustments are often required based on baseline hormone levels, ovarian reserve markers, and prior treatment outcomes. Monitoring through transvaginal ultrasound or serum estradiol measurements is recommended to tailor the treatment cycle and to minimize the chance of excessive follicular development. Pharmacokinetically, Clomiphene is absorbed slowly after oral administration, with peak plasma concentrations occurring approximately six hours post‑dose. The drug undergoes hepatic metabolism and is eliminated primarily through biliary excretion. Its half‑life can extend beyond 10 days due to active metabolites, which is why a single daily dose is sufficient to maintain therapeutic levels throughout the treatment window.

Dosage Guidelines

The standard starting regimen for Fertomid is 50 mg taken orally once daily for five consecutive days, typically beginning on the third day of the menstrual cycle (cycle day 3‑7). If ovulation does not occur after a cycle, the physician may consider increasing the dose to 100 mg daily for the next cycle. Some patients may require a further increase up to 200 mg, but doses above 200 mg have not demonstrated additional benefit and may raise the risk of adverse events. Patients are advised to take the tablet with water and to avoid crushing or splitting the tablet unless a healthcare provider specifies otherwise. It is essential to maintain a consistent dosing schedule each cycle, as missed doses can disrupt the hormonal signaling needed for follicular growth. Throughout the treatment course, clinicians often schedule ultrasound examinations on day 12‑14 to evaluate follicular size and number. If multiple mature follicles are detected, the risk of multiple pregnancy rises, and clinicians may decide to cancel the cycle or adjust the dose in subsequent cycles. For patients with hepatic impairment, a lower initial dose may be recommended because Clomiphene is metabolized in the liver. Pregnant women should discontinue the medication immediately, and a pregnancy test is typically performed before each new treatment cycle to ensure that the patient is not currently pregnant.

Side Effects

Most women tolerate Fertomid well, but like all medications, it can produce side effects. The most frequently reported adverse reactions include hot flashes, breast tenderness, abdominal discomfort, and mild nausea. These symptoms are generally transient and resolve after the medication is stopped. Some patients may experience visual disturbances such as blurred vision or floaters; although rare, these effects warrant immediate medical evaluation. More serious, though uncommon, complications can include ovarian hyperstimulation syndrome (OHSS), which manifests as abdominal swelling, rapid weight gain, and shortness of breath. If OHSS is suspected, patients should contact their physician promptly or seek emergency care. Additionally, Clomiphene may increase the likelihood of multiple gestations, which carries higher perinatal risks for both the mother and infants. Long‑term use of Clomiphene has been associated with a modest increase in the risk of ovarian tumors in animal studies, but epidemiological data in humans have not demonstrated a clear causal link. Nonetheless, clinicians typically limit treatment to a maximum of six cycles, after which alternative fertility options may be considered if pregnancy has not been achieved.

Warnings and Precautions

Fertomid is contraindicated in individuals with known hypersensitivity to Clomiphene citrate or any of the tablet excipients. It should not be used in women with active liver disease, ovarian cysts that are not related to polycystic ovary syndrome, or abnormal vaginal bleeding that has not been investigated by a healthcare professional. Patients with a history of thromboembolic disorders, endometrial hyperplasia, or estrogen‑dependent tumors should discuss the risks with their physician before initiating therapy. Because Fertomid can affect hormonal balance, it is essential to use reliable contraception unless pregnancy is an intended outcome. If a woman becomes pregnant while taking the medication, treatment should be stopped immediately, and a thorough obstetric evaluation is recommended. Additionally, patients should inform their healthcare provider of any other medications they are taking, especially those that may interact with hepatic enzymes, such as certain antifungal agents or antiepileptic drugs. It is also advisable to undergo a baseline hormonal assessment, including serum FSH, LH, estradiol, and a pelvic ultrasound, to confirm the diagnosis of ovulatory dysfunction and to rule out other underlying conditions. Regular follow‑up visits allow the clinician to monitor ovarian response and adjust dosing accordingly, thereby optimizing the chance of success while minimizing complications.

FAQs

1. What is the active ingredient in Fertomid 100 mg?
Clomiphene citrate 100 mg.

2. How many days per cycle should I take Fertomid?
Usually five days, starting on day 3‑5 of the menstrual cycle.

3. Can Fertomid increase the chance of twins?
Yes, by stimulating multiple follicles, it may raise the likelihood of a multiple pregnancy.

4. Where can I find authoritative information on Clomiphene?
Trusted sources include the NIH and the FDA.

5. Is a prescription required to purchase Fertomid?
Yes, a licensed healthcare provider must issue a prescription before dispensing the medication.

Related Products

• Misoprost 600 mcg (Misoprostol)
• Misoprost (Misoprostol)
• Misoprost 200 mcg (Misoprostol)
• Misoprostol 600 mcg (Generic)
• Misoprostol 200 mcg (Generic)
• Pantosec D SR (Pantoprazole/Domperidone)
• Pantosec D 50 Mg (Pantoprazole/Domperidone)
• Rabicip 10 mg (Rabeprazole)
• Rabicip (Rabeprazole)
• Pantosec 40 mg (Pantoprazole)
• Rabicip 20 mg (Rabeprazole)
• Rabeprazole 20 mg (Generic)